Cargando…

Cost‐effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: A Markov‐model

PURPOSE: Diabetic macular oedema (DMO), a complication of diabetes, causes vision loss and blindness. Corticosteroids are usually used as a second‐line treatment. The aim of this study was to analyse the cost‐effectiveness of dexamethasone implants compared to cheaper and more frequently applied tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pesonen, Mari, Kankaanpää, Eila, Vottonen, Pasi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597173/ https://www.ncbi.nlm.nih.gov/pubmed/33421332 http://dx.doi.org/10.1111/aos.14745

Ejemplares similares

Adverse drug events in cost-effectiveness analyses of interventions for diabetic conditions: a scoping review protocol
por: Pesonen, Mari, et al.
Publicado: (2022)

Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety
por: Mishra, S. K., et al.
Publicado: (2018)

Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
por: Karttunen, Tommi, et al.
Publicado: (2019)

Risk Factors for Refractory Diabetic Macular Oedema after Sub-Tenon's Capsule Triamcinolone Acetonide Injection
por: Oshitari, Toshiyuki, et al.
Publicado: (2015)

Intravitreal triamcinolone versus laser photocoagulation as a primary treatment for diabetic macular oedema - a comparative pilot study
por: Norlaili, Mustapha, et al.
Publicado: (2011)

Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy
por: Newcott, Eric K., et al.
Publicado: (2015)

Change in choroidal volume after dexamethasone intravitreal implant in eyes with diabetic macular oedema
por: Posch‐Pertl, Laura, et al.
Publicado: (2018)

Comparison of two techniques used in routine care for the treatment of inflammatory macular oedema, subconjunctival triamcinolone injection and intravitreal dexamethasone implant: medical and economic importance of this randomized controlled trial
por: Couret, Chloé, et al.
Publicado: (2020)

Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema
por: Obis, Javier, et al.
Publicado: (2021)

Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis
por: Majumder, Parthopratim Dutta, et al.
Publicado: (2016)

Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients
por: Dang, Yalong, et al.
Publicado: (2014)

Suprachoroidal triamcinolone acetonide versus rescue therapies for the treatment of uveitic macular oedema: A post hoc analysis of PEACHTREE
por: Singer, Michael A., et al.
Publicado: (2021)

Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration
por: Vottonen, Pasi, et al.
Publicado: (2013)

Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
por: Bhandari, Sanjeeb, et al.
Publicado: (2022)

Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study
por: Fraser-Bell, Samantha, et al.
Publicado: (2023)

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
por: Thom, Howard HZ, et al.
Publicado: (2014)

Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema
por: Abdel-Hay, Ahmed, et al.
Publicado: (2018)

Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)
por: Loutfi, Mohamed, et al.
Publicado: (2014)

Factors correlated with the resolution of macular oedema after one dose injection of intravitreal triamcinolone acetonide treatment in branch retinal vein occlusion
por: Zhang, Shuang, et al.
Publicado: (2016)

Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study
por: Mitchell, Paul, et al.
Publicado: (2023)

Visual processing in patients with age-related macular degeneration performing a face detection test
por: Vottonen, Pasi, et al.
Publicado: (2017)

Impact of metabolic control on macular thickness in diabetic macular oedema
por: Peng, Yi-Jie, et al.
Publicado: (2017)

Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema
por: Mateos-Olivares, Milagros, et al.
Publicado: (2021)

Indicators of Visual Prognosis in Diabetic Macular Oedema
por: Sen, Sagnik, et al.
Publicado: (2021)

Diabetic Macular Oedema Guidelines: An Australian Perspective
por: Yuen, Yew Sen, et al.
Publicado: (2023)

The combination of intravitreal triamcinolone and phacoemulsification surgery in patients with diabeticfoveal oedema and cataract
por: Habib, Maged S, et al.
Publicado: (2005)

Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up
por: Romero-Aroca, Pedro, et al.
Publicado: (2016)

Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema
por: Podkowinski, Dominika, et al.
Publicado: (2019)

Healthcare expenditure of intravitreal anti‐vascular endothelial growth factor inhibitors compared with dexamethasone implant for diabetic macular oedema
por: Hertzberg, Silvia NW, et al.
Publicado: (2022)

Suprachoroidal versus Intravitreal Triamcinolone Acetonide for the Treatment of Diabetic Macular Edema
por: Zakaria, Yousra Gamal, et al.
Publicado: (2022)

Intravitreal Triamcinolone Reinjection for Refractory Diabetic Macular Edema
por: Ramezani, Alireza, et al.
Publicado: (2006)

Current treatments in diabetic macular oedema: systematic review and meta-analysis
por: Ford, John Alexander, et al.
Publicado: (2013)

Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections
por: Shin, Yong Un, et al.
Publicado: (2017)

Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials
por: Danis, Ronald P, et al.
Publicado: (2016)

Intravitreal Dexamethasone Implant (IDI) Alone and Combined with Navigated 577 nm Subthreshold Micropulse Laser (SML) for Diabetic Macular Oedema
por: Toto, Lisa, et al.
Publicado: (2022)

Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema
por: Cornish, Elisa E, et al.
Publicado: (2023)

Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study
por: Rousseau, Nicolas, et al.
Publicado: (2023)

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland
por: Hallinen, Taru, et al.
Publicado: (2023)

Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema
por: Cellini, Mauro, et al.
Publicado: (2008)

Diabetic macular edema: Safe and effective treatment with intravitreal triamcinolone acetonide (Taioftal)
por: Sorrentino, Francesco Saverio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nrqm8opnpp31aboknkk3hnmo23